USA Change Macroaxis User Registration

Home Portfolios Solutions About Us

More ROI Blog

Company Contact UsPress ReleasesTerms Of UseAdvertisingWays To Invest

US Market Open: Feb 9, 12:21 PM 2012

NYSE 8085.73 2.75 Index Moved Up

NASDAQ 2926.06 10.20 Index Moved Up

and more..

sponsered by

Processing
Collecting necessary data for ALKS...

Alkermes financials and fundamentals

Companies

Sectors

Advisers

More Actions
- Equity Search
- Advanced Search
- Filter Tops
- Adviser Directory
- Suggest Portfolio
- Backtest Watchlist
- Analyze Correlations
- View Transactions
- Check Volatility
- Import Equities

18.53

Intraday

One Month

^(0.35)

1.85%

11.86

Year To Date

20.0

18.46

Trading Day

19.05

Embed Now

Diversification Suggestion

Use Alkermes to protect against small markets fluctuations. The stock experiences somewhat bearish sentiment, but market may correct it shortly

1 Month Beta vs NYSE ......... -0.23

As returns on NYSE increase, returns on owning Alkermes are expected to decrease at a much smaller rate. During bear market, Alkermes is likely to outperform the market

ALKS

NASDAQ

Alkermes Inc.

http://www.alkermes.com

353 1 772 8000

Trade Alkermes

Run Report

Correlation

Drug Delivery

Market Capitalization 2.404B

Earnings Per Share -0.60

Today Lowest 18.46

Book Value Per Share 6.974

Richard F. Pops

Chairman and Chief Officer

James M. Frates

Chief Financial Officer, Sr. VP, Pr

Gordon G. Pugh

Chief Operating Officer, Chief Risk

Dr. Elliot W. Ehrich M.D.

Chief Medical Officer and Sr. VP of

Michael J. Landine

Sr. VP of Corp. Devel.

Alkermes fundamentals

Open	19.04	P/B Ratio	2.71
Volume	230452	Sector	Healthcare
Last Close	18.88	Founded	Yes
Short Ratio	7.60	Last Traded	2/9/2012
Year High	20.00	Percent Change	1.85%
Year Low	11.86	Absolute Change	0.35
EPS	-0.60	Index Membership	Not Applicable
PEG Ratio	0.13	Employees	600
Day High	19.05	Day Low	18.46
Target Price	21.90	Current EPS	-0.60
This Year EPS	-0.62	Next Year EPS	-0.28

Alkermes Performance

Alkermes Profile

Alkermes plc, an integrated biotechnology company, develops medicines that enhance patient outcomes.

IXIC		0.35 %
GSPC		0.15 %
NYA		0.03 %
ALKS		1.85 %

Live Sentiment

CRU

TORONTO

Bought over 400 shares of

Crew Gold Corporation

28 minutes ago

for 4.64

DGS

TORONTO

Bought over 200 shares of

Dividend Growth Split Corp. Cl

28 minutes ago

for 8.58

RIM

TORONTO

Bought over 100 shares of

Research In Motion Limited

28 minutes ago

for 16.4

IMN

TORONTO

Bought over 20 shares of

Inmet Mng Corp

28 minutes ago

for 68.84

SLF

TORONTO

Bought over 90 shares of

Sun Life Financial Inc.

28 minutes ago

for 21.17

Alkermes 30-Days Moving Rating

Macroaxis Total Score

Current 30 Days Moving Rating

Estimated Market Risk

1.7

actual daily

71 %

of total potential

Expected Return

0.19

actual daily

15 %

of total potential

Risk-Adjusted Return

0.11

actual daily

7 %

of total potential

Based on monthly moving average [ change ]

Increase Risk-Adjusted return of ALKS by adding it to a well-diversified portfolio

Diversify

Alkermes Last Intraday

(0.35) Macroaxis: -0.35 Up

1.85%

18.88,18.88,18.53,18.53,19.05,18.46,18.53

18.88

18.53

Latest headlines for Alkermes

Few days ago at www.bioresearchonline.com

FDA Approves BYDUREON? ? The First And Only Once-Weekly

San Diego, CA and Dublin, Ireland /PRNewswire/ - Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes plc (Nasdaq: ALKS) today announced that the US Food and Drug Administration (FDA) has approved BYDUREON? (exenatide extended-release for ...

Few days ago at www.zacks.com

Zyprexa Pulls Down Lilly's 4Q Sales

Eli Lilly & Company (LLY) reported fourth quarter 2011 adjusted earnings per share of 87 cents, 7 cents above the Zacks Consensus Estimate but 24 cents below the year-ago earnings of $1.11.

Few days ago at www.zacks.com

Zyprexa Pulls Down Lilly's 4Q Sales

Eli Lilly & Company (LLY) reported fourth quarter 2011 adjusted earnings per share of 87 cents, 7 cents above the Zacks Consensus Estimate but 24 cents below the year-ago earnings of $1.11.

Few days ago at www.thestreet.com

Alkermes Initiates Open-Label Pilot Study Of VIVITROL? To Evaluate Impact On ...

Alkermes Initiates Open-Label Pilot Study Of VIVITROL? To Evaluate Impact On ... TheStreet.com (press release) - Jan 31, 2012 By Business Wire 01/31/12 - 07:00 AM EST Alkermes plc (NASDAQ: ALKS) today announced the initiation of a pilot study of VIVITROL? (naltrexone for extended-release injectable suspension) in prisoners with a pre-incarceration history of opioid dependence ...

Few days ago at www.thestreet.com